致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2023年11月30日 狀態: 新提交 呈交日期: 2023年12月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底法定/註冊 ...

公司名稱： 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期： 2023年11月27日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 09969 | 說明 | | | | | | 發行股份 | (註6及7) | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | 於下列日期開始時的結存(註2) | 2023年11月14日 | 1,498,662,235 | | | | | | 1). 購回股份(或其他證券)但沒有註銷 | | 32,000 | 0.0021 % | | | % | | 變動日期 | 2023年11月14日 | | | | | | | 2). 購回股份(或其他證券)但沒有註銷 | ...

| 2. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市(註11) | 否 | | | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如於香港聯交所上市) | | 說明 | 該等股份為於上海證券交易所科創板上市的股票 | | | | | 發行股份 | | | 已發行股份佔 有關股份發行前的 | 每股發行價 | 上一個營業日 | 發行價較市值的折讓/ | | (註6及7) | | 股份數目 | 現有已發行股份數目 | (註1及7) | 的每股收市價 | 溢價幅度(百分比) | | | | | 百分比 | | (註5) | (註7) | | | | | (註4、6及7) | | | | FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期： 2023年11月14日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份 ...

Financial Performance - The company achieved a total revenue of RMB 537.36 million for the first nine months of 2023, representing a year-on-year growth of 21.7%[3] - The adjusted net profit for the first nine months of 2023, excluding non-cash items, was a loss of RMB 322 million, while the total net profit was a loss of RMB 539 million, narrowing the loss by RMB 304 million compared to the same period last year[3] - The net profit attributable to shareholders for the third quarter was a loss of RMB 108.96 million, with a basic and diluted earnings per share of -0.06 yuan[5] - The company reported a net loss of ¥4,979,423,376.98 for the first three quarters of 2023, compared to a net loss of ¥4,448,257,868.41 in the same period of 2022[17] - The company's net profit for the first three quarters of 2023 was -539,287,265.88 RMB, compared to -842,652,515.00 RMB in the same period of 2022, showing an improvement of approximately 36%[19] - The company's total comprehensive income for the first three quarters of 2023 was -337,601,250.11 RMB, compared to -279,487,002.07 RMB in 2022[20] - The basic earnings per share for 2023 was -0.31 RMB, an improvement from -0.59 RMB in 2022[20] - The operating profit for the first three quarters of 2023 was -548,854,514.11 RMB, an improvement from -842,055,946.80 RMB in 2022, indicating a recovery trend[19] Cash Flow and Assets - As of September 30, 2023, the company held cash and cash equivalents of approximately RMB 8.58 billion, ensuring sufficient cash flow for ongoing projects[4] - Cash and cash equivalents were reported at ¥8,261,546,048.38, down from ¥8,742,914,140.21 at the end of 2022[16] - The total current assets amounted to ¥8,945,496,793.93, a decrease from ¥9,299,708,518.08 at the end of 2022[16] - The total assets of the company as of the end of the reporting period were RMB 10.04 billion, a decrease of 2.80% compared to the previous year[6] - The total assets as of September 30, 2023, were ¥10,039,622,087.37, compared to ¥10,328,783,979.11 at the end of 2022[17] - The total liabilities as of September 30, 2023, were ¥2,659,650,754.08, slightly down from ¥2,684,457,313.64 at the end of 2022[17] - The company’s cash and cash equivalents at the end of the period increased to 5,440,243,367.28 RMB from 4,414,372,466.48 RMB in the previous year, marking a growth of approximately 23.2%[22] Research and Development - The company's R&D expenditure for the third quarter was RMB 188.52 million, accounting for 117.97% of the revenue, an increase of 17.26 percentage points year-on-year[5] - Research and development expenses increased to 549,716,988.65 RMB in 2023 from 475,344,994.01 RMB in 2022, reflecting a growth of about 15.6%[19] - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[15] Shareholder Information - The number of common shareholders at the end of the reporting period was 20,286[11] - The largest shareholder, HKSCC NOMINEES LIMITED, holds 728,962,157 shares, representing 41.32% of total shares[11] Revenue Sources - The sales growth of the drug Oubatinib (Yinokai®) significantly contributed to the revenue increase since its inclusion in the new medical insurance catalog[3] - Total revenue for the first three quarters of 2023 reached ¥537,361,649.40, an increase of 21.7% compared to ¥441,612,184.36 in the same period of 2022[18] - Total operating costs for the first three quarters of 2023 were ¥1,088,452,691.35, down 16.4% from ¥1,301,756,168.51 in the previous year[18] - The company reported government subsidies of RMB 4.98 million for the third quarter, contributing to its financial performance[7] - The company’s sales revenue from goods and services received cash of 552,799,573.58 RMB in 2023, up from 389,838,923.35 RMB in 2022, representing a growth of about 41.8%[21]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 (1) 2023年第三季度季度報告 此部分公告乃由諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司 證券上市規則（「上市規則」）第13.09(2)(a)條及第13.10B條及香港法例第571章證 券及期貨條例第XIVA部的內幕消息條文作出。 茲載列本公司在上海證券交易所網站刊發的《諾誠健華醫藥有限公司2023年第三 季度報告》（「2023年第三季度報告」），僅供參閱。以下為本公司2023年第三季度 報告的譯文，僅供參考。如有任何歧義，概以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒本公司股東及潛在投資者，本公告所載 資料及財務數據未經審計，已經本公司審核委員會審閱，但未經本公司獨立核數 師審閱。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9969） (1) 2023年第三季度季度報告 及 (2) 關於20 ...

Financial Performance - InnoCare Pharma achieved a revenue of HKD 537 million for the first nine months of 2023, representing a year-on-year growth of 21.7%[14] - The adjusted net loss for the first nine months of 2023 was HKD 322 million, while the total net loss was HKD 539 million, a reduction of HKD 304 million compared to the same period last year[14] - The company's operating revenue for the reporting period was RMB 159.81 million, representing a decrease of 18.32% compared to the same period last year[16] - The net profit attributable to shareholders was a loss of RMB 108.96 million, with a year-to-date loss of RMB 531.17 million[16] - The company reported a net loss of RMB 4,979,423,376.98 for the first three quarters of 2023, compared to a net loss of RMB 4,448,257,868.41 in the same period of 2022[28] - The net profit attributable to shareholders of the parent company was -531,165,508.57 CNY, compared to -834,150,562.18 CNY in the previous year, showing an improvement of approximately 36.3%[31] - The total comprehensive income for the period was -337,601,250.11 CNY, compared to -279,487,002.07 CNY in the same period last year[31] Research and Development - The company is focusing on expanding its research and development capabilities, particularly in clinical trials and internal discovery projects[5] - InnoCare aims to strengthen its capabilities in discovery, clinical development, and commercialization by hiring domestic and international talents[8] - Research and development expenses totaled RMB 188.52 million, accounting for 117.97% of operating revenue, an increase of 17.26 percentage points year-on-year[16] - Research and development expenses increased to 549,716,988.65 CNY in 2023 from 475,344,994.01 CNY in 2022, reflecting a rise of about 15.6%[30] Cash and Liquidity - As of September 30, 2023, the company held cash and cash equivalents of approximately RMB 8.58 billion, ensuring sufficient cash reserves for ongoing project advancements[15] - Cash and cash equivalents as of September 30, 2023, amounted to RMB 8,261,546,048.38, a decrease from RMB 8,742,914,140.21 at the end of 2022[27] - The cash and cash equivalents at the end of the period amounted to 5,440,243,367.28 CNY, up from 4,414,372,466.48 CNY in the previous year, indicating a growth of approximately 23.2%[33] Shareholder Information - The total number of issued shares was 1,764,321,452, with 85% listed on the Hong Kong Stock Exchange[21] - The top ten shareholders collectively held 73.00% of the company's shares, with HKSCC NOMINEES LIMITED holding 41.32%[22] Strategic Plans - The company plans to utilize the remaining funds from the fundraising activities completed in February 2021 within three years, depending on actual business needs[9] - The total net amount raised from the February 2021 fundraising was approximately HKD 3,041 million[6] - The company is also reserving funds for potential external collaborations and licensing opportunities[9] - The company plans to continue focusing on R&D and market expansion strategies to enhance future growth prospects[30] Financial Position - Total assets decreased by 2.80% to RMB 10.04 billion compared to the previous year-end[17] - The equity attributable to shareholders decreased by 3.37% to RMB 7.34 billion compared to the previous year-end[17] - Total liabilities as of September 30, 2023, were RMB 2,659,650,754.08, compared to RMB 2,684,457,313.64 at the end of 2022, showing a slight decrease of about 0.9%[28] - The company's total equity as of September 30, 2023, was RMB 7,379,971,333.29, down from RMB 7,644,326,665.47 at the end of 2022[28] Government Support - The company recognized government subsidies amounting to RMB 4.98 million during the reporting period[18] Financial Reporting - The financial data presented in the report is unaudited and based on Chinese accounting principles[1]

FF304 翌日披露報表 (股份發行人 ── 已發行股本變動及/或股份購回) 表格類別： 股票 狀態： 新提交 公司名稱： 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期： 2023年11月8日 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市(註11) | 是 | | | 證券代號 (如於香港聯交所上市) | 09969 | 說明 | | | | | | | 發行股份 (註6及7) | 股份數目 | 已發行股份佔 有關股份發行前的 現有已發行股份數目 百分比 (註4、6及7) | 每股發行價 (註1及7) | 上一個營業日 的每股收市價 (註5) | 發行價較市值的折讓/ 溢價幅度(百分比) (註7) | | | 於下列日期開始時的結存(註2) 2023年10月31日 | 1,499,673,235 | | | | | | 1). | 購回股份(或其他證券) 並已註銷 | -133,000 | 0.00887 % | | | % | ...

| A 股代码：688428 | A 股简称：诺诚健华 | 公告编号：2023-030 | | --- | --- | --- | | 港股代码：09969 | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 11 月 14 日(星期二)上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 11 月 7 日(星期二)至 11 月 13 日(星期一)16:00 前登 录上证路演中心网站首页点击 " 提问预征集 " 栏目或通过公司邮箱 IR@innocarepharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答 诺诚健华医药有限公司（以下简称"公司"）将于 2023 年 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2023年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 | 09969 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | 0.000002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 6 頁 v 1.0.2 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 董事會召開日期 諾誠健華醫藥有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將於 2023年11月13日（星期一）舉行董事會會議，藉以（其中包括）考慮並批准本公司 及其附屬公司截至2023年9月30日止九個月之未經審計第三季度業績及其發佈。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9969） 香港，2023年11月1日 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士； 非執行董事施一公博士、謝榕剛先生及金明先生；以及獨立非執行董事胡蘭女 士、陳凱先博士及董丹丹博士。 ...